VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice

Area of Science:

• Gastroenterology
• Microbiology
• Oncology

Background:

• Ulcerative colitis (UC) poses a significant risk for colorectal cancer development.
• The gut microbiota plays a crucial role in the pathogenesis and progression of UC-associated carcinogenesis.
• Modulating the gut microbiota through probiotics may offer a therapeutic strategy for preventing UC-associated tumors.

Purpose of the Study:

• To evaluate the efficacy of VSL#3, a probiotic formulation, in preventing tumor formation in a mouse model of ulcerative colitis (UC).
• To assess the impact of VSL#3 on fecal and intestinal mucosal microbiota composition in the context of UC-associated carcinogenesis.
• To investigate the effects of VSL#3 on inflammatory markers in the colon.

Main Methods:

• Azoxymethane/dextran sulfate sodium (AOM/DSS) was used to induce a UC carcinogenesis model in C57BL/6 mice.
• Mice were treated with 5-aminosalicylic acid (5-ASA), VSL#3, or a combination of both for three months.
• Tumor load, colonic levels of TNF-α and IL-6, and gut microbiota composition (via 16s rDNA sequencing) were analyzed.

Main Results:

• VSL#3 treatment significantly reduced tumor load and decreased levels of TNF-α and IL-6 in the colon.
• Fecal microbiota analysis revealed alterations in bacterial populations, with VSL#3 and 5-ASA modulating levels of Lactobacillus, Oscillibacter, and Lachnoclostridium.
• Intestinal mucosal microbiota showed increased Bifidobacterium and decreased Alloprevotella following VSL#3 supplementation.

Conclusions:

• VSL#3 demonstrates preventative effects against UC-associated carcinogenesis in a mouse model.
• VSL#3 effectively reduces colonic mucosal inflammation.
• VSL#3 contributes to rebalancing the fecal and mucosal intestinal microbiota, suggesting a role in maintaining gut homeostasis.